cnbc.com / .cnbc-com-health-care / Page 4

Eli Lilly is slated to report first-quarter earnings before the bell on Thursday, in one of the most closely watched reports across the health-care sector.

Novartis' CEO warned Tuesday that U.S. drug pricing policy under President Donald Trump poses a "very difficult situation."

Novartis, Amgen and Eli Lilly are betting that slashing levels of a particularly bad form of cholesterol could deliver the next blockbusters in cardiology.

Spotify teams with Peloton to launch fitness content, potentially opening new revenue streams while expanding Peloton's global reach.

Intellia Therapeutics said its Crispr-based treatment for hereditary angioedema met its goals in a Phase 3 trial, marking a milestone for gene editing.

Regeneron will make its newly approved gene therapy available for free in the U.S. The company hasn't yet decided how much it will charge in other countries.

CNBC's Jim Cramer urged investors to look beyond the market's high-flying names and focus on already beaten-down sectors.

Regeneron is the latest in a string of major drugmakers to make pricing concessions for new and existing medicines under agreements with Trump.

Trump administration to reclassify marijuana as Schedule III, easing research barriers but not legalizing the drug or changing current federal penalties.

A ban on TV junk food ads would likely draw fierce backlash from major food manufacturers.